FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of immune cytokines; it can be used in medicine for the therapy of immune disorders. Proposed protein based on an antibody with grafted cytokine contains a variable region of a heavy chain (VH) containing complementarity determining regions (hereinafter – CDR), HCDR1 with SEQ ID NO: 17, HCDR2 with SEQ ID NO: 18, HCDR3 with SEQ ID NO: 19; and a variable region of a light chain (VL) containing LCDR1 with SEQ ID NO: 30, LCDR2 with SEQ ID NO: 31, LCDR3 with SEQ ID NO: 32; and an interleukin 2 (hereinafter – IL2) molecule grafted on HCDR1.
EFFECT: invention provides preferable binding and stimulation of signal transmission by means of a high-affinity receptor of IL2 relatively to a low-affinity receptor of IL2; increase or maintenance of Treg activity without increase in activity of CD8+ T-cells, Tcon, or NK-cells; improved half-life, stability, and production possibility compared to the known compositions based on recombinant human IL2.
26 cl, 20 dwg, 2 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-BASED PROTEINS WITH CYTOKINE GRAFTS AND METHODS OF THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2815389C2 |
IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
Authors
Dates
2022-12-26—Published
2018-05-22—Filed